Literature DB >> 2116803

Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes.

J O Miners1, K J Lillywhite, K Yoovathaworn, M Pongmarutai, D J Birkett.   

Abstract

A specific high performance liquid chromatographic assay has been developed for the measurement of paracetamol glucuronide formation by the microsomal fraction of human liver. The procedure has been used to characterize paracetamol glucuronidation kinetics in human livers microsomes and to assess the substrate specificity of the paracetamol UDP-glucuronosyltransferase (UDPGT) activity. Paracetamol glucuronidation followed Michaelis-Menten kinetics, suggesting the involvement of a single form of UDPGT, or possibly two or more forms of UDPGT with similar affinities for paracetamol, in this reaction. Mean apparent Km and Vmax values were 7.37 +/- 0.99 mM and 4.76 +/- 1.35 nmol/min/mg, respectively. Addition of the non-ionic detergent Brij 58 to microsomal incubations resulted in approximately 50% activation of microsomal paracetamol UDPGT-activity. This contrasts to the approximately three-fold activation of 4-methylumbelliferone, morphine and 4-nitrophenol glucuronidation observed following Brij 58 treatment of human liver microsomes. The glucuronidated xenobiotics chloramphenicol, digitoxigenin monodigitoxoside, 4-hydroxybiphenyl, 4-methylumbelliferone, morphine, 1-naphthol and 4-nitrophenol were screened for inhibitory effects on paracetamol glucuronidation. Of these compounds, only digitoxigenin monodigitoxoside and 1-naphthol were found to cause significant inhibition of paracetamol UDPGT activity. Along with the results of previous studies of the kinetics and inhibitor profile of human liver glucuronidation reactions (Miners et al., Biochem Pharmacol 37: 665-671, 1988 and 37: 2839-2845, 1988), these data indicate that the model glucuronidated substrates paracetamol, morphine and 4-methyllumbelliferone may be used to differentiate at least four human liver UDPGT isozyme activities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116803     DOI: 10.1016/0006-2952(90)90561-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man.

Authors:  A Somogyi; F Bochner; Z R Chen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Mathematical modelling of fluid flow and solute transport to define operating parameters for in vitro perfusion cell culture systems.

Authors:  Lauren Hyndman; Sean McKee; Nigel J Mottram; Bhumika Singh; Steven D Webb; Sean McGinty
Journal:  Interface Focus       Date:  2020-02-14       Impact factor: 3.906

3.  Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study.

Authors:  Ann M Moyer; Brooke L Fridley; Gregory D Jenkins; Anthony J Batzler; Linda L Pelleymounter; Krishna R Kalari; Yuan Ji; Yubo Chai; Kendra K S Nordgren; Richard M Weinshilboum
Journal:  Toxicol Sci       Date:  2010-12-22       Impact factor: 4.849

4.  Excretion of tacrolimus glucuronides in human bile.

Authors:  I Firdaous; R K Verbeeck; A Hassoun; J M Langrehr; P E Wallemacq
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

5.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 6.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Novobiocin inhibits both UDP-glucuronosyltransferase and cytochrome P450-mediated enzyme activities in pig liver microsomes.

Authors:  D Villar; N Furusawa; M Monshouwer; A S Van Miert
Journal:  Vet Res Commun       Date:  1998-09       Impact factor: 2.459

8.  Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Authors:  Shufan Ge; Yifan Tu; Ming Hu
Journal:  Curr Pharmacol Rep       Date:  2016-11-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.